Bogoch II, Watts A, Thomas-Bachli A, Huber C, Kraemer MUG, Khan K. Potential for global spread of a novel coronavirus from China. J Travel Med. 2020;27(2):taaa011. https://doi.org/10.1093/jtm/taaa011.
Cucinotta D, Vanelli M. WHO declares COVID-19 a pandemic. Acta Biomed. 2020;91(1):157–60. https://doi.org/10.23750/abm.v91i1.9397.
Gupta SL, Jaiswal RK. Neutralizing antibody: a savior in the Covid-19 disease. Mol Biol Rep. 2022;49:2465–74. https://doi.org/10.1007/s11033-021-07020-6.
World Health Organization. WHO Coronavirus (COVID-19) Dashboard 2023. Cited 2023. Available from: https://covid19.who.int/. Accessed Sept 2023./vaccines?m49=818&n=c. Accessed March 18, 2024
Lim S, Bae JH, Kwon HS, Nauck MA. COVID-19 and diabetes mellitus: from pathophysiology to clinical management. Nat Rev Endocrinol. 2021;17(1):11–30. https://doi.org/10.1038/s41574-020-00435-4.
Deng J, Ma Y, Liu Q, Du M, Liu M, Liu J. Severity and outcomes of SARS-CoV-2 reinfection compared with primary infection: a systematic review and meta-analysis. Int J Environ Res Public Health. 2023;20:3335. https://doi.org/10.3390/ijerph20043335.
Sinclair AH, Taylor MK, Weitz JS, Beckett SJ, Samanez-Larkin GR. Reasons for receiving or not receiving bivalent COVID-19 booster vaccinations among adults-United States, november 1-december 10, 2022. MMWR Morb Mortal Wkly Rep. 2023;72(3):73–5. https://doi.org/10.15585/mmwr.mm7203a5.
Hodgson SH, Mansatta K, Mallett G, Harris V, Emary KRW, Pollard AJ. What defines an efficacious COVID-19 vaccine? A review of the challenges assessing the clinical efficacy of vaccines against SARS-CoV-2. Lancet Infect Dis. 2021;21(2):e26–35. https://doi.org/10.1016/S1473-3099(20)30773-8.
Fang E, Liu X, Li M, et al. Advances in COVID-19 mRNA vaccine development. Signal Transduct Target Ther. 2022;7(1):94. https://doi.org/10.1038/s41392-022-00950-y.
Excler JL, Saville M, Privor-Dumm L, et al. Factors, enablers and challenges for COVID-19 vaccine development. BMJ Glob Health. 2023;8:e011879. https://doi.org/10.1136/bmjgh-2023-011879.
Lopez Bernal J, Andrews N, Gower C, Gallagher E, Simmons R, Thelwall S, Stowe J, Tessier E, Groves N, Dabrera G, Myers R, Campbell CNJ, Amirthalingam G, Edmunds M, Zambon M, Brown KE, Hopkins S, Chand M, Ramsay M. Effectiveness of Covid-19 vaccines against the B.1.617.2 (Delta) variant. N Engl J Med. 2021;385:585–94.
Polack FP, Thomas SJ, Kitchin N, et al. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. N Engl J Med. 2020;383:2603–15. https://doi.org/10.1056/NEJMoa2034577.
Zheng J, Deng Y, Zhao Z, et al. Characterization of SARS-CoV-2-specific humoral immunity and its potential applications and therapeutic prospects. Cell Mol Immunol. 2022;19(2):150–7. https://doi.org/10.1038/s41423-021-00774-w.
Gudbjartsson DF, Norddahl GL, Melsted P, et al. Humoral immune response to SARS-CoV-2 in iceland. N Engl J Med. 2020;383(18):1724–34. https://doi.org/10.1056/NEJMoa2026116.
Favresse J, Gillot C, Di Chiaro L, et al. Neutralizing antibodies in COVID-19 patients and vaccine recipients after two doses of BNT162b2. Viruses. 2021;13(7):1364. https://doi.org/10.3390/v13071364.
Cromer D, Steain M, Reynaldi A, Schlub TE, Wheatley AK, Juno JA, Kent SJ, Triccas JA, Khoury DS, Davenport MP. Neutralising antibody titres as predictors of protection against SARS-CoV-2 variants and the impact of boosting: a meta-analysis. Lancet Microbe. 2022;3:e52-61. https://doi.org/10.1016/S2666-5247(21)00267-6.
Gilbert PB, Montefiori DC, McDermott AB, Fong Y, Benkeser D, Deng W, Zhou H, Houchens CR, Martins K, Jayashankar L, et al. Immune correlates analysis of the mRNA-1273 COVID-19 vaccine efficacy clinical trial. Science. 2022;375:43–50. https://doi.org/10.1126/science.abm3425.
Hernández AF, Calina D, Poulas K, Docea AO, Tsatsakis AM. Safety of COVID-19 vaccines administered in the EU: should we be concerned? Toxicol Rep. 2021;8:871–9. https://doi.org/10.1016/j.toxrep.2021.04.003.
Saker K, Pozzetto B, Escuret V, et al. Evaluation of commercial Anti-SARS-CoV-2 neutralizing antibody assays in seropositive subjects. J Clin Virol. 2022;152:105169. https://doi.org/10.1016/j.jcv.2022.105169.
Perera RAPM, Ko R, Tsang OTY, et al. Evaluation of a SARS-CoV-2 surrogate virus neutralization test for detection of antibody in human, canine, cat, and hamster sera. J Clin Microbiol. 2021;59(2):e02504-20. https://doi.org/10.1128/JCM.02504-20.
Morales-Núñez J, Muñoz-Valle J, Meza-López C, Wang L, Sulbarán A, Torres-Hernández P, Bedolla-Barajas M, et al. Neutralizing antibodies titers and side effects in response to BNT162b2 vaccine in healthcare workers with and without prior SARS-CoV-2 infection. Vaccines. 2021;9(742):1–13.
Taylor SC, Hurst B, Charlton CL, et al. A new SARS-CoV-2 dual-purpose serology test: highly accurate infection tracing and neutralizing antibody response detection. J Clin Microbiol. 2021;59:e02438-20. https://doi.org/10.1128/JCM.02438-20.
Garcia-Beltran WF, Lam EC, Astudillo MG, et al. COVID-19-neutralizing antibodies predict disease severity and survival. Cell. 2021;184(2):476-488.e11. https://doi.org/10.1016/j.cell.2020.12.015.
Sette A, Crotty S. Immunological memory to SARS-CoV-2 infection and COVID-19 vaccines. Immunol Rev. 2022;310(1):27–46. https://doi.org/10.1111/imr.13089.
Virk A, Johnson MG, Roellinger DL, et al. Hybrid immunity provides protective advantage over vaccination or prior remote coronavirus disease 2019 alone. Open Forum Infect Dis. 2023;10(5):161. https://doi.org/10.1093/ofid/ofad161.
León TM, Dorabawila V, Nelson L, et al. COVID-19 cases and hospitalizations by COVID-19 mvaccination status and previous COVID-19 diagnosis—California and New York, May–November 2021. MMWR Morb Mortal Wkly Rep. 2022;71(4):125–31. https://doi.org/10.15585/mmwr.mm7104e1.
Cui J, Li F, Shi ZL. Origin and evolution of pathogenic coronaviruses. Nat Rev Microbiol. 2019;17:181–92.
Collier DA, Ferreira IATM, Kotagiri P, et al. Age-related immune response heterogeneity to SARS-CoV-2 vaccine BNT162b2. Nature. 2021;596:417–22. https://doi.org/10.1038/s41586-021-03739-1.
Evans JP, Zeng C, Carlin C, et al. Neutralizing antibody responses elicited by SARS-CoV-2 mRNA vaccination wane over time and are boosted by breakthrough infection. Sci Transl Med. 2022;14(637):8057. https://doi.org/10.1126/scitranslmed.abn8057.
Nanda R, Gupta P, Giri AK, Patel S, Shah S, Mohapatra E. Serological evaluation of antibody titers after vaccination against COVID-19 in 18–44-year-old individuals at a tertiary care center. Cureus. 2023;15(6):e40543. https://doi.org/10.7759/cureus.40543.
Khoury DS, Cromer D, Reynaldi A, et al. Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection. Nat Med. 2021;27(7):1205–11. https://doi.org/10.1038/s41591-021-01377-8.
Adjobimey T, Meyer J, Sollberg L, et al. Comparison of IgA, IgG, and neutralizing antibody responses following immunization with moderna, BioNTech, AstraZeneca, Sputnik-V, Johnson and Johnson, and Sinopharm’s COVID-19 vaccines. Front Immunol. 2022;13:917905. https://doi.org/10.3389/fimmu.2022.917905.
van Gils MJ, Lavell A, van der Straten K, et al. Antibody responses against SARS-CoV-2 variants induced by four different SARS-CoV-2 vaccines in health care workers in the Netherlands: a prospective cohort study. PLoS Med. 2022;19(5):e1003991. https://doi.org/10.1371/journal.pmed.1003991.
Wei J, Pouwels KB, Stoesser N, et al. Antibody responses and correlates of protection in the general population after two doses of the ChAdOx1 or BNT162b2 vaccines. Nat Med. 2022;28:1072–82. https://doi.org/10.1038/s41591-022-01721-6.
Sahin U, Muik A, Derhovanessian E, et al. COVID-19 vaccine BNT162b1 elicits human antibody and TH1 T cell responses. Nature. 2020;586(7830):594–9.
Dos Santos WG. Natural history of COVID-19 and current knowledge on treatment therapeutic options. Biomed Pharmacother. 2020;129:110493. https://doi.org/10.1016/j.biopha.2020.110493.
Sahin U, Karikó K, Türeci Ö. mRNA-based therapeutics–developing a new class of drugs. Nat Rev Drug Discov. 2014;13(10):759–80.
Earle KA, Ambrosino DM, Fiore-Gartland A, et al. Evidence for antibody as a protective correlate for COVID-19 vaccines. Vaccine. 2021;39:4423–8.
Pouwels KB, Pritchard E, Matthews PC, et al. Effect of Delta variant on viral burden and vaccine effectiveness against new SARS-CoV-2 infections in the UK. Nat Med. 2021;27:2127–35. https://doi.org/10.1038/s41591-021-01548-7.
El Sahly HM, Baden LR, Essink B, et al. Efficacy of the mRNA-1273 SARS-CoV-2 vaccine at completion of blinded phase. N Engl J Med. 2021;385(19):1774–85. https://doi.org/10.1056/NEJMoa2113017.
Wang Z, Muecksch F, Schaefer-Babajew D, et al. Naturally enhanced neutralizing breadth against SARS-CoV-2 one year after infection. Nature. 2021;595:426–31. https://doi.org/10.1038/s41586-021-03696-9.
Muecksch F, Wang Z, Cho A, et al. (2022) Increased potency and breadth of SARS-CoV-2 neutralizing antibodies after a third mRNA vaccine dose. BioRxiv. 2022;02:14.480394. https://doi.org/10.1101/2022.02.14.480394.
Goel RR, Painter MM, Apostolidis SA, et al. mRNA vaccines induce durable immune memory to SARS-CoV-2 and variants of concern. Science. 2021;374(6572):abm0829. https://doi.org/10.1126/science.abm0829.
Chia WN, Zhu F, Ong SWX, et al. Dynamics of SARS-CoV-2 neutralising antibody responses and duration of immunity: a longitudinal study. Lancet Microbe. 2021;2(6):e240-9. https://doi.org/10.1016/S2666-5247(21)00025-2.
Ebinger JE, Fert-Bober J, Printsev I, Wu M, Sun N, Prostko JC, Frias EC, Stewart JL, Van Eyk JE, Braun JG, et al. Antibody responses to the BNT162b2 mRNA vaccine in individuals previously infected with SARS-CoV-2. Nat Med. 2021;27:981–4.
Discover more from PressNewsAgency
Subscribe to get the latest posts sent to your email.